Rivet PVS Therapy in Group 2C

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with symptomatic pulmonary hypertension.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Select Inclusion Criteria:

- Age ≥ 18 years.

- Prior diagnosis of Group 2 PH due to HFpEF, with the following resting hemodynamic criteria confirmed in the past year by right heart catheterization.

a. mPAP ≥ 25 mmHg at rest or mPAP/CO slope > 3 mmHg/L/min during incremental exercise.

- Confirmation of the following hemodynamic criteria during supine exercise.

a. PCWP ≥ 25 mmHg, or PCWP/CO slope > 2 mmHg/L/min.

- Chronic symptomatic heart failure documented by the following:

1. NYHA HF Class II with history > II, or Class III or ambulatory Class IV.

2. ≥ 1 HF hospitalization, or healthcare facility with IV diuretics or intensification of oral diuresis for HF within 12 months, or NT-pro BNP value > 400 pg/mL in normal sinus rhythm or > 750 pg/mL in atrial fibrillation in past 6
months.

- Ongoing stable guideline directed medical therapy (GDMT) for HF and medically optimized per treating HF physician according to current ACCF/AHA guidelines that is
expected to be maintained without change for 6 months (excluding diuretic dosage changes for HF optimization within 90 days of the Index Procedure).

- 6MWD ≥ 150 m.

Select Exclusion Criteria:

- Any therapeutic intracardiac intervention within the last 30 days.

- PH Group 1, 3, 4 or 5.

- Mean RAP >12 mmHg by RHC at rest on room air.

- Right ventricular dysfunction, defined as one or more of the following.

1. Greater than moderate RV dysfunction as assessed by TTE and/or MRI.

2. RV FAC < 35%.

3. TAPSE < 14 mm via TTE.

4. RV size severely enlarged compared to LV size as estimated by TTE and/or MRI.

- Severe tricuspid valve regurgitation.

- Peak systolic pulmonary arterial pressure > 80 mmHg by RHC at rest while awake.

- Mean pulmonary arterial pressure > 50 mmHg by RHC at rest while awake.

- PVR > 6 Wood units at rest while awake on room air or exercise PVR > 2 Wood Units.

- Left ventricular ejection fraction < 50%.

- Severe heart failure, defined as one or more of the following:.

1. ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF.

2. If BMI < 30, Cardiac Index < 2.0 L/min/m^2.

3. If BMI ≥ 30, Cardiac Index < 1.8 L/min/m^2.

4. Requires continuous intravenous inotropic infusion.

5. Requires mechanical circulatory support.

6. Currently on the cardiac transplant waiting list.

- Chronic renal dysfunction defined as one or more of the following:

1. Currently requiring dialysis; OR

2. eGFR < 35 mL/min/1.73 m2 by the CKD-Epi equation.

- Chronic pulmonary disease defined as one or more of the following:

1. Requires continuous home oxygen therapy;

2. Recent hospitalization for exacerbation within 12 months prior to screening;

3. FEV1 < 50% predicted.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/17/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Trevor Simard, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Trevor Simard M.D., Ph.D.

(507) 284-6945

Simard.Trevor@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20544194

Mayo Clinic Footer